

BSKB, LLP, 8110 Gatehouse Rd, Suite 100E, Falls Church, VA 22042

## facsimile transmittal

To: **Examiner M. Allen** Fax: **(571)273-0712**  
From: **Eugene T. Perez (Reg. No. 48,501)** Date: **6/29/2009**  
Re: **Applic. No. 10/569,791** Pages: **2 (Including cover)**  
Confirm **6478**  
ation  
No.:

Urgent       For review       Please comment       Please reply       Please recycle

---

**Notes:** Attached is a proposed new claim for our discussions tomorrow. Thank you and sincerely,

Eugene Perez  
(703) 208-4006



CONFIDENTIAL

Application Number: 10/569,791  
Attorney Docket No.: 1254-0305PUS1

**Proposed Claim Amendments**

**DO NOT ENTER – FOR DISCUSSION PURPOSES ONLY**

**PRIVILEGED AND  
CONFIDENTIAL  
MATERIAL**

42. (New) A screening method for a candidate antidiabetic substance, comprising the steps of:

bringing a candidate diabetic substance into contact with a target protein represented by the following (a) or (b):

(a) a protein consisting of the amino acid sequence represented by SEQ ID NO: 2;

or

(b) a protein consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 (i) with the addition of one or plural amino acids and/or (ii) with the deletion, substitution, or insertion of one to thirty amino acids, wherein the protein having the derived amino acid sequence has at least 90% homology with SEQ ID NO: 2; and

screening for the presence or absence of an interaction between the candidate antidiabetic substance and the target protein represented by (a) or (b).

[Please see specification at page 8, paragraph after formula (III); paragraph bridging pages 9-10; page 14, last paragraph; page 15, lines 3-20.] [Regarding a candidate substance interacting with protein (a) or (b) and having a mechanism of action similar to pioglitazone, please see page 11, line 4 to page 14, line 21; pioglitazone is known to have antidiabetic effects as disclosed in the FDA website: see, e.g., <http://www.fda.gov/bbs/topics/ANSWERS/ANS00965.html>].